Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Novo Nordisk A/S (NYSE:NVO), the maker of the popular obesity drug Ozempic, has been reprimanded by the U.K.'s Prescription Medicines Code of Practice Authority (PMCPA) for failing to disclose fees and expenses paid to individuals and organizations in Britain of approximately 7.8 million pounds (around $10 million) between 2020 and 2022.
诺和诺德制药（NYSE:NVO）生产的主流币药物Ozempic被英国处方药物行为规范局（PMCPA）谴责，因未披露2020年至2022年期间向英国个人和组织支付的费用和开支约780万英镑（约1000万美元）
On Friday, the U.K. industry body PMCPA announced that the reprimand followed a voluntary submission by Novo Nordisk regarding these payments.
英国行业机构PMCPA周五宣布，这次谴责是基于诺和诺德自愿提交有关这些支付情况的结果。
Also Read: Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs.
还读：乔·拜登建议Novo Nordisk和Lilly降低其主流币肥胖症药物的价格。
The PMCPA stated that the payments involved over 150 bodies, including fees and expenses to health professionals, donations, grants, sponsorships, and other payments to healthcare organizations.
PMCPA称这些支付涉及150多个机构，包括向卫生专业人士支付费用和支出、捐款、拨款、赞助以及向医疗保健组织支付的其他费用。
Reuters report added that Novo Nordisk explained that these payments were for legitimate activities but were incorrectly categorized in their finance systems due to human error.
路透社的报道还指出，诺和诺德解释称这些支付是用于合法的活动，但由于人为失误错误地分类在他们的财务系统中。
The PMCPA also reported breaches of the Association of the British Pharmaceutical Industry's (ABPI) code of practice by Novartis AG (NYSE:NVS) and Pfizer Inc (NYSE:PFE).
PMCPA还报告了诺华制药（NYSE:NVS）和辉瑞公司（NYSE:PFE）违反了英国药品工业协会（ABPI）的行为准则。
The agency noted that the breaches discredited and reduced confidence in the pharmaceutical industry.
该机构指出，这些违规行为使药品行业声誉受损，削弱了公众对药品行业的信恳智能。
In March 2023, Novo Nordisk was suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to serious ABPI Code of Practice breaches.
2023年3月，由于严重违反英国药品工业协会行为准则，诺和诺德被暂停成为英国药品工业协会会员两年。
ABPI's statement linked to a complaint alleging that Novo Nordisk sponsored courses on weight management on LinkedIn for health professionals without clarifying the company's involvement.
ABPI的声明与一项投诉有关，指控诺和诺德在领英上赞助了有关体重管理课程的课程，但没有说明公司的参与情况。
Price Action: NVO shares are
价格走势：NVO股票
- Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds.
- 使用肥胖症药物？研究发现，诺和诺德的Ozempic和Wegovy可能导致视力丧失疾病。
Photo via Shutterstock
图片来自shutterstock。